CytoDyn Names Robert E. Hoffman as New CEO

VANCOUVER, Washington, Oct. 19, 2026 /CourierPR/ -- CytoDyn, a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, has announced a significant leadership transition. Effective October 20, 2026, Robert E. Hoffman will take over as Chief Executive Officer, succeeding Dr. Jacob Lalezari, who has served as CEO since November 2023.

Dr. Lalezari will continue to contribute to the company in a new role as Head of Research and Translational Sciences. His focus will be on identifying and advancing new opportunities for leronlimab in solid-tumor oncology. The leadership change comes as CytoDyn prepares for its next phase of clinical development, with a focus on advancing its oncology pipeline, pursuing regulatory milestones, and exploring potential strategic partnerships.

Mr. Hoffman, who first joined CytoDyn on May 15, 2025, originally serving as its Chief Financial Officer, brings extensive financial and leadership experience to the role. He is an industry veteran with decades of experience, having served in executive and board roles at several biotech companies. Most recently, he was the President, CEO, interim Chief Financial Officer, and Chairperson of the board of directors of Kintara Therapeutics, Inc. Prior to that, he held senior positions at Heron Therapeutics, Inc., Innovus Pharmaceuticals, Inc., and AnaptysBio, Inc.

Mr. Hoffman holds a B.B.A. from St. Bonaventure University and has served on the board of directors of TuHURA Biosciences and Fibrobiologics, Inc. He is a former member of the steering committee of the Association of Bioscience Financial Officers and served as a director and President of the San Diego Chapter of Financial Executives International from 2010 to 2020. He was also an advisor to the Financial Accounting Standards Board from 2010 to 2020.

CytoDyn is dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. The company is committed to improving patients' quality of life through therapeutic innovation and is focused on its clinical pipeline, regulatory milestones, and strategic partnerships.